Risankizumab safe, effective at 52 weeks for psoriatic arthritis

Risankizumab provides long-term benefits in patients with psoriatic arthritis (PsA) who have not achieved adequate response to previous therapies, according to a study recently published in Rheumatology.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup